The total return over the past 12 months is +164.01% vs. +16.94% for the S&P 500. So far it's up +19.70% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +164.01% | +71.53% | +26.35% | N/A | N/A | N/A |
| Total Return CAGR | +164.01% | +74.47% | +27.64% | N/A | N/A | N/A |
| Revenue CAGR | (100.00%) | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Inhibrx Biosciences Inc. (INBX)
| Year | Start price | End price | INBX Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $79.00 | $94.56 | +19.70% | +14.51% | +5.19% |
| 2025 | $15.40 | $79.00 | +412.99% | +17.72% | +395.27% |
| 2024 | $38.00 | $15.40 | (57.35%) | +24.89% | (82.24%) |
| 2023 | $24.64 | $38.00 | +54.22% | +26.19% | +28.03% |
| 2022 | $43.67 | $24.64 | (43.58%) | (18.17%) | (25.41%) |
| 2021 | $32.97 | $43.67 | +32.45% | +28.74% | +3.71% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
